Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print August 23, 2007
DOI: 10.2337/db07-0681

This Article
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-0681v1
56/12/2854    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kramer, H. F.
Right arrow Articles by Goodyear, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kramer, H. F.
Right arrow Articles by Goodyear, L. J.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

THE CALMODULIN-BINDING DOMAIN OF AS160 REGULATES CONTRACTION- BUT NOT INSULIN-STIMULATED GLUCOSE UPTAKE IN SKELETAL MUSCLE

Henning F. Kramer*, Eric B. Taylor*, Carol A. Witczak*, Nobuharu Fujii*, Michael F. Hirshman*, and Laurie J. Goodyear*,,{dagger}

*Joslin Diabetes Center Research Division, Metabolism, Boston, MA, USA
{dagger}Brigham and Women's Hospital and Harvard Medical School, Medicine, Boston, MA, USA

Objective.: Insulin and contraction increase skeletal muscle glucose uptake through distinct and additive mechanisms. However, recent reports have demonstrated that both signals converge on AS160, a protein that regulates GLUT4 translocation. Although AS160 phosphorylation is believed to be the primary factor affecting its activity, AS160 also possesses a calmodulin-binding domain (CBD). This raises the possibility that contraction-stimulated increases in Ca2+/calmodulin could also modulate AS160 function.

Research Design and Methods.: To evaluate the AS160 CBD in skeletal muscle, empty-vector, wild-type or CBD-mutant AS160 cDNAs were injected into mouse muscles followed by in vivo electroporation. One-week later, AS160 was overexpressed by ~14-fold over endogenous protein.

Results.: Immunoprecipitates of wild-type and CBD-mutant AS160 were incubated with biotinylated-calmodulin in the presence of Ca2+. Wild-type AS160, but not the CBD-mutant AS160, associated with calmodulin. Next, we measured insulin- and contraction-stimulated glucose uptake in vivo. Compared to empty-vector and wild-type AS160, insulin-stimulated glucose uptake were not altered in muscles expressing CBD-mutant AS160. In contrast, contraction-stimulated glucose uptake was significantly decreased in CBD-mutant expressing muscles. This inhibitory effect on glucose uptake was not associated with aberrant contraction-stimulated AS160 phosphorylation. Interestingly, AS160 expressing both calmodulin-binding and Rab-GAP domain point mutations (CBD+R/K) fully restored contraction-stimulated glucose uptake.

Conclusions.: Our results suggest that the AS160 CBD directly regulates contraction-induced glucose uptake in mouse muscle, and that calmodulin provides an additional means of modulating AS160 Rab-GAP function independent of phosphorylation. These findings define a novel AS160 signaling component, unique to contraction and not insulin, leading to glucose uptake in skeletal muscle.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.